Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The T790M and C797S mutations of the epidermal growth factor receptor gene (EGFR) confer resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs), respectively, in patients with non-small cell lung cancer (NSCLC) harboring activating mutations of EGFR. C797S has been identified in cis or in trans with T790M in tumor specimens from patients who experienced treatment failure with first- and third-generation EGFR-TKIs. The allelic relation between T790M and activating mutations of EGFR has not been well characterized, however. We have now developed a digital polymerase chain reaction (dPCR)-based method for determination of the allelic relation between two types of EGFR mutation (T790M and either C797S or an activating mutation).

          Related collections

          Author and article information

          Journal
          Lung Cancer
          Lung cancer (Amsterdam, Netherlands)
          Elsevier BV
          1872-8332
          0169-5002
          June 2017
          : 108
          Affiliations
          [1 ] Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8128582, Japan.
          [2 ] Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8128582, Japan; Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka 8128582, Japan. Electronic address: iwama@kokyu.med.kyushu-u.ac.jp.
          [3 ] Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8128582, Japan; Division of Epigenomics and Development, Medical Institute of Bioregulation, Kyushu University, Fukuoka 8128582, Japan.
          [4 ] Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka 8128582, Japan.
          [5 ] Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka 8128582, Japan.
          [6 ] Division of Epigenomics and Development, Medical Institute of Bioregulation, Kyushu University, Fukuoka 8128582, Japan.
          Article
          S0169-5002(17)30237-4
          10.1016/j.lungcan.2017.02.019
          28625653

          Comments

          Comment on this article